Tau Isoform Regulation in Neurodegenerative Diseases
Principal Investigator
Ian d'Souza, PhD
University of Washington School of Medicine
Seattle, WA, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2004 - March 31, 2006
Grant ID
A2004285
Summary
Dementia affects more than 20 million people worldwide and more than 4 million people in the United States. Alzheimer’s disease (AD) and frontotemporal dementia (FTD) are two of the most common forms of dementia. Toxic, insoluble aggregates of tau protein, called neurofibrillary tangles (NFTs) are pathological signatures in AD and FTD. The amount of tau accumulation correlates with disease severity, but its role in the initiation of the disease is unknown. The objective of Dr. D’Souza’s research is to understand the mechanism for tau gene expression during normal development, normal aging, and disease development in cell cultures and mouse neuronal systems. Mice bred to express the human tau genomic construct will be a powerful system to study tau gene expression during brain development and aging, and could help identify new candidates for therapeutic interventions.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD